Navigation Links
Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lilly's Beamline Capabilities
Date:7/14/2011

INDIANAPOLIS, July 14, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and the U.S. Department of Energy's Argonne National Laboratory announced today the completion of Lilly's $2 million upgrade to the company's research-guided beamline, located at the Advanced Photon Source (APS) at Argonne's campus outside of Chicago. The APS is a U.S. Department of Energy Office of Science User Facility operated by Argonne.

The Lilly Research Laboratories Collaborative Access Team (LRL-CAT) beamline is a sophisticated x-ray analytical facility that produces detailed, atom-by-atom pictures of protein crystals. Its operations rely on the high-quality x-rays generated by the APS, one of the most powerful sources of x-rays for research purposes worldwide.

The data produced by the beamline and interpreted by LRL scientists provide valuable information on the interactions between potential new medicines and human disease protein targets. Lilly chemists, structural biologists, and the staff at the LRL-CAT beamline facility work together to create molecules, prepare crystals and analyze how the molecules bind to the proteins. The process is iterative, initially using beamline data to design new potential medicines with enhanced properties, which are in turn introduced into protein crystals and then re-analyzed.  

The LRL-CAT upgrade included an automation component that allows unattended operation of the beamline for extended periods. Previously, LRL-CAT employees worked in shifts on nights and weekends to maintain throughput. They can now monitor and, if necessary, operate the facility from remote locations using the Internet. The result is that Lilly scientists are able to get the data they need, as quickly as possible, in order to make informed decisions on the development of future Lilly medicines. The cost of the upgrade was funded by Lilly and supports LRL's objective of producing more "timely shots in goal," in other words, getting medicines approved and available as quickly as possible to the patients who are waiting.

A simple way to think about the work Lilly scientists are conducting at its beamline facility is to view the disease protein they are studying as the "lock" and the molecule as the "key." The beamline helps researchers determine if the molecule (the key) can unlock the protein disease target (the lock) and therefore change its behavior.

To do this, Lilly chemists typically develop large numbers of molecules (keys) and add the molecules to the protein disease target (locks), developed by Lilly structural biologists, to create protein crystals. Once this process is complete, the crystals are sent to the LRL-CAT beamline facility via overnight delivery for analysis. The LRL-CAT beamline utilizes x-rays to determine if and how the molecule was able to "unlock" the protein, usually within minutes of acquisition. Based on the results from the data, Lilly scientists are able to quickly create better "keys." The facility currently examines more than 10,000 protein crystals per year and supports nearly half of Lilly's research portfolio.

"Utilizing the team and beamline at Argonne to develop potential medicines to treat diseases like Alzheimer's is a great example of technology and the human mind coming together. Lilly scientists utilized beamline data to help design our beta-secretase inhibitor which is currently in Phase I clinical testing to determine its potential as a treatment for Alzheimer's disease. In this specific instance they have come together literally to learn to save the human mind," said Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories.

"The APS has long been a hotspot of pharmaceutical research and has become an increasingly important tool for Lilly and other pharmaceutical companies in the research and development of new medicines," said Argonne Director Eric Isaacs. "The collaboration between Lilly and Argonne serves as an example of how researchers from different sectors can work together on the most pressing problems facing the public."

About Argonne National Laboratory

Argonne National Laboratory seeks solutions to pressing national problems in science and technology. The nation's first national laboratory, Argonne conducts leading-edge basic and applied scientific research in virtually every scientific discipline. Argonne researchers work closely with researchers from hundreds of companies, universities, and federal, state and municipal agencies to help them solve their specific problems, advance America's scientific leadership and prepare the nation for a better future. With employees from more than 60 nations, Argonne is managed by UChicago Argonne, LLC for the U.S. Department of Energy's Office of Science.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

(Logo: http://photos.prnewswire.com/prnh/20110714/DE35167LOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 CBG ... the PW Series Solvent Recycling Systems, specifically designed ... full integration with new and existing vapor degreasers, ... produces consistently-fresh solvent through continuous recycling and recovers ... --> --> Precision parts ...
(Date:2/8/2016)... 2016 --> ... "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, ... Surgery, Ophthalmology, Gynecology) - Global Forecasts to 2020", published ... the forecast period of 2015 to 2020. The market ... CAGR of 10.5% from 2015 to 2020. ...
(Date:2/8/2016)... EAST NORRITON, Pa. , Feb. 8, 2016 ... acquisition of November Research Group (NRG),s pharmacovigilance ... of pharmacovigilance system-related consulting services and an Oracle ... regulatory compliance services to Life Sciences companies. ... acquisition strengthens and expands HighPoint,s life sciences capabilities ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... Shark Finds and Kevin Harrington, and the Product Managers ... , GRIP-DRY is a newly patented product that has solved some of the basic problems ... and early morning dew or right after a rain shower, might understand the struggle of ...
(Date:2/8/2016)... ... February 08, 2016 , ... CURE Media Group , the nation’s ... Multiple Myeloma Heroes Awards event , which will annually honor individuals making heroic ... with MM. The MM Heroes Awards nomination process is officially open through ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , ... Food & Beverage and Dietary Supplement market segments across the ... USA geographies east of the Rocky Mountains since 2012. Consistent performance in ...
(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
(Date:2/8/2016)... Angeles, CA (PRWEB) , ... February 08, 2016 , ... A man who has struggled ... of Freedom Laser Therapy , was determined to find solutions to his problems – ... of Inventors Digest is ready to introduce his breakthrough inventions to the world ...
Breaking Medicine News(10 mins):